First half of 2018 revenues
01/10/2018 – AB Science reports its revenues for the first half of 2018 and provides an update on its activities.
Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
23/07/2018 – A trend analysis for OS was planned after a certain number of events are observed.
Results of the Combined General Shareholders’ Meeting held on June 29 2018
03/07/2018 – The voting details for each resolution are available in the Investor Relations section of the website.
Combined General Shareholders’ Meeting held on June 29, 2018
03/07/2018 – Presentation of the current situation and future prospects.
Positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in first-line treatment of castrate-resistant prostate cancer
19/06/2018 – AB Science expects study to be completed in 2019.
Update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis
28/05/2018 – AB Science is evaluating the possibility to resubmit the application based on the final results from study AB10015.
Annual Financial Results as of December 31, 2017
30/04/2018 – AB Science reports on its annual financials as of 31 December 2017 and provides an update on its activities.
CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis
19/04/2018 – AB Science will provide additional data through a reexamination procedure
Corporate Presentation
13/03/2018 – Current status and perspective for 2018.
IDMC recommended the continuation of the masitinib phase 3 study in progressive forms of multiple sclerosis with no requirement to increase the study sample size
04/01/2018 – Additionally, the IDMC did not report any safety concern with masitinib in the study population.